The firm plans to use the proceeds to advance its pipeline of T-cell receptor therapies and support their manufacturing, production, and commercialization.
The drugmaker wants to establish Enhertu in HER2-ultralow breast cancer and even HER2-negative tumors but remains committed to precision medicine strategies.
The firm will use the court-administered restructuring process to pursue strategic alternatives so it can continue developing vaccines and immunotherapies.
Immatics raised $175 million in a previous public stock offering earlier this year, and $110 million in a previous private stock offering in October 2022.
The firm is evaluating leniolisib, which is already approved and sold under the brand name Joenja for APDS, in certain primary immunodeficiencies with immune dysregulation.
The Boston-based firm just launched the first trial of a CDK12/13 inhibitor and is anticipating starting Phase III trials for a CDK7 inhibitor in 2026.
After seeing a 100 percent response rate in Phase I, Indian health authorities said the firm can test ribrecabtagene autoleucel in Phase II of the SWASTH trial.